3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
Specimen Handling
49
Letrozole
42
Fulvestrant
42
Paclitaxel
38
pembrolizumab
34
Magnetic Resonance Spectroscopy
31
Carboplatin
31
ribociclib
26
Trastuzumab
26
Biopsy
26
exemestane
23
Anastrozole
23
Capecitabine
22
palbociclib
21
pertuzumab
20
Tamoxifen
19
trastuzumab deruxtecan
18
abemaciclib
18
Cyclophosphamide
17
Taxes
15
Radiotherapy
14
130-nm albumin-bound paclitaxel
12
elacestrant
11
Docetaxel
11
sacituzumab govitecan
9
olaparib
9
Standard of Care
9
Radiation
9
Goserelin
9
Gemcitabine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Imlunestrant
×
Breast
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT07287098
2026-05-22
preEMBER
Eli Lilly and Company
Phase 2
Not yet recruiting
600 enrolled